Article references (34 references )


  1. Nunes ML, Tabarin A. Les actualités de l'insuffisance surrénalienne. Ann Endocrinol. 2008; 69: S44-52. PubMed | Google Scholar

  2. Erichsen MM, Løvås K, Skinningsrud B, Wolff AB, Undlien DE, Svartberg J et al. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. J Clin Endocrinol Metab. 2009; 94(12): 4882-90. PubMed | Google Scholar

  3. Menon S, Kuhn J-M. Insuffisance surrénalienne. Encycl Med Chir (Elsevier Masson, Paris Endocrinologie-Nutrition). 2011; 10-015-A-10. In press.

  4. Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD et al. Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016; 101(2): 364-89. PubMed | Google Scholar

  5. Falorni A, Minarelli V, Morelli S. Therapy of adrenal insufficiency: an update. Endocrine. 2013; 43(3): 514-28. PubMed | Google Scholar

  6. Oksnes M, Ross R, Løvås K. Optimal glucocorticoid replacement in adrenal insufficiency. Best Pract Res Clin Endocrinol Metab. 2015; 29(1): 3-15. PubMed | Google Scholar

  7. Bergthorsdottir R, Leonsson-Zachrisson M, Odén A, Johannsson G. Premature Mortality in Patients with Addison's Disease: a Population-Based Study. J Clin Endocrinol Metab. 2006; 91(12): 4849-53. PubMed | Google Scholar

  8. Aulinas A, Casanueva F, Goñi F, Monereo S, Moreno B, Picó A et al. Adrenal insufficiency and adrenal replacement therapy: current status in Spain. Endocrinol Nutr. 2013; 60(3): 136-43. PubMed | Google Scholar

  9. Leelarathna L, Breen L, Powrie JK, Thomas SM, Guzder R, McGowan B et al. Co-morbidities, management and clinical outcome of auto-immune Addison's disease. Endocrine. 2010; 38(1): 113-7. PubMed | Google Scholar

  10. Filipsson H, Monson JP, Koltowska-Häggström M, Mattsson A, Johannsson G. The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab. 2006; 91(10): 3954-61. PubMed | Google Scholar

  11. Johannsson G, Nilsson AG, Bergthorsdottir R, Burman P, Dahlqvist P, Ekman B et al. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J Clin Endocrinol Metab. 2012;97(2): 473-81. PubMed | Google Scholar

  12. Giordano R, Marzotti S, Balbo M, Romagnoli S, Marinazzo E, Berardelli R et al. Metabolic and cardiovascular profile in patients with Addison's disease under conventional glucocorticoid replacement. J Endocrinol Invest. 2009; 32(11): 917-23. PubMed | Google Scholar

  13. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab. 2003; 88(6): 2404-11. PubMed | Google Scholar

  14. Alonso N, Granada ML, Lucas A, Salinas I, Reverter J, Oriol A et al. Evaluation of two replacement regimens in primary adrenal insufficiency patients: effect on clinical symptoms, health-related quality of life and biochemical parameters. J Endocrinol Invest. 2004; 27(5): 449-54. PubMed | Google Scholar

  15. Mah PM, Jenkins RC, Rostami-Hodjegan A, Newell-Price J, Doane A, Ibbotson V et al. Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clin Endocrinol (Oxf). 2004; 61(3): 367-75. PubMed | Google Scholar

  16. Løvås K, Husebye ES. High prevalence and increasing incidence of Addison's disease in western Norway. Clin Endocrinol (Oxf). 2002; 56(6): 787-91. PubMed | Google Scholar

  17. Andersson DKG, Svärdsudd K, Tibblin G. Prevalence and Incidence of Diabetes in a Swedish Community 1972-1987. Diabet Med. 1991; 8(5): 428-34. PubMed | Google Scholar

  18. Debono M, Ross RJ, Newell-Price J. Inadequacies of glucocorticoid replacement and improvements by physiological circadian therapy. Eur J Endocrinol. 2009; 160(5): 719-29. PubMed | Google Scholar

  19. Plat L, Byrne MM, Sturis J, Polonsky KS, Mockel J, Féry F et al. Effects of morning cortisol elevation on insulin secretion and glucose regulation in humans. Am J Physiol. 1996; 270: E36-42. PubMed | Google Scholar

  20. Heureux F, Maiter D, Boutsen Y, Devogelaer JP, Jamart J, Donckier J. Évaluation de la substitution par corticostéroïdes et de ses répercussions osseuses dans la maladie d'Addison. EM consulte. 2006; 61(3): 179-83. PubMed | Google Scholar

  21. Hazra A, Pyszczynski NA, DuBois DC, Almon RR, Jusko WJ. Modeling of corticosteroid effects on hepatic low-density lipoprotein receptors and plasma lipid dynamics in rats. Pharm Res. 2008; 25(4): 769-80. PubMed | Google Scholar

  22. Nanjee MN, Miller NE. Plasma lipoproteins and adrenocortical hormones in men-positive association of low density lipoprotein cholesterol with plasma cortisol concentration. Clin Chim Acta. 1989; 180(2): 113-20. PubMed | Google Scholar

  23. Ross IL, Bergthorsdottir R, Levitt N, Dave JA, Schatz D, Marais D et al. Cardiovascular risk factors in patients with Addison's disease: a comparative study of South African and Swedish patients. PLoS One. 2014; 9(3): 1-6. PubMed | Google Scholar

  24. Danilowicz K, Bruno OD, Manavela M, Gomez RM, Barkan A. Correction of cortisol overreplacement ameliorates morbidities in patients with hypopituitarism: a pilot study. Rev Argent Endocrinol Metab. 2009; 46(2): 25-34. PubMed | Google Scholar

  25. Gurnell EM, Hunt PJ, Curran SE, Conway CL, Pullenayegum EM, Huppert FA et al. Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial. J Clin Endocrinol Metab. 2008; 93(2): 400-9. PubMed | Google Scholar

  26. Ross IL, Bergthorsdottir R, Levitt NS, Schatz DA, Johannsson G, Marais AD. Increased cardiovascular risk in South African patients with addison's disease. Horm Metab Res. 2013; 45(12): 905-10. PubMed | Google Scholar

  27. Ettinger WH, Hazzard WR. Prednisone increases very low density lipoprotein and high density lipoprotein in healthy men. Metabolism. 1988; 37(11): 1055-8. PubMed | Google Scholar

  28. Beentjes JA, van Tol A, Sluiter WJ, Dullaart RP. Decreased plasma cholesterol esterification and cholesteryl ester transfer in hypopituitary patients on glucocorticoid replacement therapy. Scand J Clin Lab Invest. 2000; 60(3): 189-98. PubMed | Google Scholar

  29. Van der Westhuyzen DR, de Beer FC, Webb NR. HDL cholesterol transport during inflammation. Curr Opin Lipidol. 2007; 18(2): 147-51. PubMed | Google Scholar

  30. Quinkler M, Hahner S. What is the best long-term management strategy for patients with primary adrenal insufficiency? Clin Endocrinol (Oxf). 2012; 76(1): 21-5. PubMed | Google Scholar

  31. Devogelaer JP, Crabbé J, Nagant de Deuxchaisnes C. Bone mineral density in Addison's disease: evidence for an effect of adrenal androgens on bone mass. Br Med J (Clin Res Ed). 1987; 294(6575): 798-800. PubMed | Google Scholar

  32. Bensing S, Brandt L, Tabaroj F, Sjöberg O, Nilsson B, Ekbom A et al. Increased death risk and altered cancer incidence pattern in patients with isolated or combined autoimmune primary adrenocortical insufficiency. Clin Endocrinol (Oxf). 2008; 69(5):697-704. PubMed | Google Scholar

  33. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004; 141(10): 764-70. PubMed | Google Scholar

  34. McFarlane SI, Sowers JR. Cardiovascular endocrinology 1: aldosterone function in diabetes mellitus: effects on cardiovascular and renal disease. J Clin Endocrinol Metab. 2003; 88(2): 516-23. PubMed | Google Scholar